TREM1+ regulatory myeloid cells expand in steatohepatitis-HCC and associate with poor prognosis and therapeutic resistance to immune checkpoint blockade
J. Giraud, D. Chalopin, E. Ramel, T. Boyer, A. Zouine, M.-A. Derieppe, N. Larmonier, O. Adotevi, B. Le Bail, J.-F. Blanc, L. Chiche, M. Nikolski, M. Saleh
This study identifies TREM1+CD163+ regulatory myeloid cells in steatohepatitis-HCC that suppress T cell function and are linked to poor prognosis and resistance to immune checkpoint therapy.
bioRxiv · Nov 9, 2022 · PreprintImmunology